カテゴリ： GlobalData, アメリカ, 企業調査

Ligand Pharmaceuticals Inc (LGND)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Ligand Pharmaceuticals Inc (LGND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012274
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：133
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Ligand Pharmaceuticals Inc (Ligand) develops and acquires technologies that help in discovery and development of medicines. The company provides a diversified portfolio of biotechnology and pharmaceutical products. Its marketed product portfolio encompasses indication for fungal infections, hepatitis C, Idiopathic thrombocytopenic purpura (ITP), multiple myeloma, cancer, osteoporosis, and severe aplastic anemia. Ligand’s clinical development portfolio comprises medications targeted at the treatment of seizure, cancer, diabetes, coma, cardiovascular disease, liver disease, muscle wasting, kidney disease, and others. In partnership with other pharmaceutical companies the company also offers late-stage development, regulatory management and commercialization support. Ligand is headquartered in San Diego, California, the US.

Ligand Pharmaceuticals Inc (LGND) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 20
Venture Financing 22
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 22
Partnerships 23
Ligand Pharma Enters into Agreement with AiCuris 23
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 24
Symphogen Enters Into Agreement With Open Monoclonal Technology 25
Open Monoclonal Expands Agreement with CNA Development 26
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 27
Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 28
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 29
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 30
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 31
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 32
WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 33
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 34
Licensing Agreements 35
Amgen Enters into Licensing Agreement with Ligand Pharma 35
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 36
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 37
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 38
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 39
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 40
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 41
Novartis Enters into Licensing Agreement with Ligand Pharma 42
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 43
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 44
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 45
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 46
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 47
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 48
Sanofi Enters into Licensing Agreement with Ligand Pharma 49
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 50
Open Monoclonal Enters into Licensing Agreement with Celgene 51
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 52
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 53
Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 54
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 56
Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 57
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 58
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 59
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 60
TeneoBio Enters into Licensing Agreement with Ligand Pharma 61
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 62
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 63
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 64
RODES Enters into Licensing Agreement with Ligand Pharma 65
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 66
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 67
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 68
Open Monoclonal Enters into Licensing Agreement with Amgen 69
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 70
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 71
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 72
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 73
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 74
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 75
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 76
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 77
Ligand Pharma Enters Into Licencing Agreement With Merck 78
Ligand Pharma Enters Into Licensing Agreement With Hospira 79
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 80
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 81
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 82
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 83
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 84
Equity Offering 86
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 86
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 87
Debt Offering 88
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 88
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 90
Acquisition 91
Ligand Pharma to Acquire Crystal Bioscience 91
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 93
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology’s Spin-Out Companies 94
Ligand Pharma Acquires CyDex Pharma 95
Ligand Pharmaceuticals Inc – Key Competitors 97
Ligand Pharmaceuticals Inc – Key Employees 98
Ligand Pharmaceuticals Inc – Locations And Subsidiaries 99
Head Office 99
Other Locations & Subsidiaries 99
Recent Developments 101
Financial Announcements 101
Nov 09, 2017: Ligand Reports Third Quarter 2017 Financial Results 101
Aug 07, 2017: Ligand Reports Second Quarter 2017 Financial Results 104
May 09, 2017: Ligand Reports First Quarter 2017 Financial Results 107
Feb 23, 2017: Ligand Reports Fourth Quarter and Full Year 2016 Financial Results 110
Nov 03, 2016: Ligand Reports Third Quarter 2016 Financial Results 113
Aug 04, 2016: Ligand Reports Second Quarter 2016 Financial Results 116
May 04, 2016: Ligand Reports First Quarter 2016 Financial Results 119
Feb 10, 2016: Ligand Reports Fourth Quarter and Full Year 2015 Financial Results 122
Corporate Communications 125
Aug 21, 2017: Ligand Appoints Dr. Nancy Gray to its Board of Directors 125
Clinical Trials 126
Feb 27, 2017: Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes 126
Sep 13, 2016: Ligand Initiates Phase 2 Trial with LGD-6972 in Type 2 Diabetes 127
Aug 15, 2016: Results from Phase 1 Trials with Ligand LGD-6972 in Type 2 Diabetes Mellitus Published in Diabetes, Obesity and Metabolism 128
Other Significant Developments 130
Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb® platform to develop fully human antibodies 130
Feb 28, 2017: Ligand Provides Highlights From Analyst Day Event 131
Appendix 133
Methodology 133
About GlobalData 133
Contact Us 133
Disclaimer 133

List of Tables
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 8
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 9
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 10
Ligand Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 11
Ligand Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 13
Ligand Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 14
Ligand Pharma Acquires Financial Rights to More Than 15 Biologic Development Programs from Selexis for USD4 Million 19
Ligand Pharma Acquires Financial Rights To Over 15 Biologic Development Programs Of Selexis For Up To US$4.5 Million 20
Nucorion Pharma Raises USD5 Million in Series A Venture Financing 22
Ligand Pharma Enters into Agreement with AiCuris 23
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 24
Symphogen Enters Into Agreement With Open Monoclonal Technology 25
Open Monoclonal Expands Agreement with CNA Development 26
Hovione FarmaCiencia Enters Into Co-Promotion Agreement With Ligand For Captisol Technology 27
Wuxi PharmaTech Enters Into Agreement With Open Monoclonal Technology For OmniRat Antibody 28
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 29
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 30
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 31
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 32
WuXi PharmaTech And Open Monoclonal Technology Enter Into Agreement For OmniRat Antibody 33
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 34
Amgen Enters into Licensing Agreement with Ligand Pharma 35
Surface Oncology Enters into Licensing Agreement with Ligand Pharma 36
xCella Biosciences Enters into Licensing Agreement with Ligand Pharma 37
Interventional AnalgesiX Enters into Licensing Agreement with Ligand Pharma for Captisol 38
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 39
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 40
Ono Pharma Enters into Licensing Agreement with Ligand Pharma 41
Novartis Enters into Licensing Agreement with Ligand Pharma 42
Seelos Therapeutics Enters into Licensing Agreement with Ligand Pharma 43
ABBA Therapeutics Enters into Licensing Agreement with Ligand Pharma 44
Tizona Therapeutics Enters into Licensing Agreement with Ligand Pharma 45
Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 46
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 47
Sage Therapeutics Enters into Licensing Agreement with Ligand Pharma 48
Sanofi Enters into Licensing Agreement with Ligand Pharma 49
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 50
Open Monoclonal Enters into Licensing Agreement with Celgene 51
Sermonix Pharma Expands Licensing Agreement with Ligand Pharma for Lasofoxifene 52
Ligand Pharma Enters into Licensing Agreement with TG Therapeutics for IRAK-4 Inhibitor Program 53
Viking Therapeutics Amends Licensing Agreement with Ligand Pharma 54
Ligand Pharma Enters Into Licensing Agreement With Omthera Pharma 56
Sage Therapeutics Amends its Licensing Agreement with CyDex Pharma 57
Azure Biotech Enters Into Licensing Agreement With Ligand Pharma For Lasofoxifene 58
Ligand Pharma Enters Into Licensing Agreement With Spectrum Pharma For Captisol-Enabled Melphalan 59
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 60
TeneoBio Enters into Licensing Agreement with Ligand Pharma 61
Nucorion Pharma Enters into Licensing Agreement with Ligand Pharma 62
Gilead Sciences Enters into Licensing Agreement with Ligand Pharma 63
XTL Biopharma Enters into Licensing Agreement with CyDex Pharma 64
RODES Enters into Licensing Agreement with Ligand Pharma 65
Vireo Health Enters into Licensing Agreement with Ligand Pharmaceuticals 66
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 67
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 68
Open Monoclonal Enters into Licensing Agreement with Amgen 69
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 70
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 71
Ligand Pharma Extends Licensing Agreement With CURx Pharma for Topiramate Lamotrigine 72
Ligand Pharma Enters into Licensing Agreement with Avion Pharma for Captisol 73
Ligand Pharma Enters Into Licensing Agreement With CURx Pharma For Topiramate Injection 74
Ligand Pharma Enters Into Licensing Agreement With Ethicor For Oral Lasofoxifene 75
MEI Pharma Enters into Licensing Agreement with Ligand Pharma 76
MEI Pharma Enters into Licensing Agreement with CyDex Pharma 77
Ligand Pharma Enters Into Licencing Agreement With Merck 78
Ligand Pharma Enters Into Licensing Agreement With Hospira 79
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 80
Ligand Pharma Enters Into Licensing Agreement With Sage Therapeutics 81
Ligand Pharma Enters Into Licensing Agreement With Chiva Pharma For Fablyn 82
Ligand Pharma Enters Into Licensing Agreement With The Medicines Company 83
Ligand Enters Into Licensing Agreement With Chiva For Pradefovir And MB01733 84
Ligand Pharma Completes First Tranche Of Public Offering Of Securities For US$2.7 Million 86
Ligand Pharma Announces Private Placement Of Common Stock For US$30 Million 87
Ligand Pharma Raises USD245 Million in Private Placement of 0.75% Notes Due 2019 88
Viking Therapeutics Raises USD2.5 Million in Private Placement of Notes 90
Ligand Pharma to Acquire Crystal Bioscience 91
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 93
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 94
Ligand Pharma Acquires CyDex Pharma 95
Ligand Pharmaceuticals Inc, Key Competitors 97
Ligand Pharmaceuticals Inc, Key Employees 98
Ligand Pharmaceuticals Inc, Subsidiaries 99

★海外企業調査レポート[Ligand Pharmaceuticals Inc (LGND)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Chevron Corporation：企業の戦略・SWOT・財務情報
    Chevron Corporation - Strategy, SWOT and Corporate Finance Report Summary Chevron Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Contact Energy Ltd (CEN)：石油・ガス：M&Aディール及び事業提携情報
    Summary Contact Energy Ltd (Contact Energy) is an energy company that generates electricity and sells electricity, natural gas and liquefied petroleum gas to customers. It generates electricity from various sources of energy including thermal, hydro and geothermal sources of energy. It supplies elec …
  • Anthem Inc (ANTM)：製薬・医療：M&Aディール及び事業提携情報
    Summary Anthem Inc (Anthem), formerly WellPoint Inc, is a health benefits company. It offers managed healthcare related products and administrative services. The company provides various specialty and insurance products and services including radiology benefit management, dental, life and disability …
  • Advanced Accelerator Applications SA (AAAP)-医療機器分野：企業M&A・提携分析
    Summary Advanced Accelerator Applications SA (AAA) is a healthcare products provider that offers molecular nuclear medicine and diagnostic and therapeutic products. The company’s lead product candidate comprises Lutathera, a lutetium-177 somatostatin analogue peptide that is used for the treatment o …
  • TESARO Inc (TSRO)：製薬・医療：M&Aディール及び事業提携情報
    Summary TESARO Inc (TESARO) is an oncology-focused biopharmaceutical company that focuses on developing in-licensed, oncology-related product candidates and discovery of new candidates. It develops products using different approaches, comprising small molecules and immuno-oncology antibodies. The co …
  • Bonheur ASA (BON)：企業の財務・戦略的SWOT分析
    Summary Bonheur ASA (Bonheur) is an oil and gas investment service provider that offers investment services for various energy sectors. The company invests in renewable energy, cruise, shipping and offshore wind, offshore drilling, and other investments. It operates shipping vessels for transport an …
  • Tianjin Zhongxin Pharmaceutical Group Corp Ltd (600329)-製薬・医療分野：企業M&A・提携分析
    Summary Tianjin Zhongxin Pharmaceutical Group Corp Ltd (TZPG) manufactures and markets traditional Chinese medicine, western medicine and health products. The company offers Chinese patent medicines, Chinese medicinal materials, western medicines, dietary supplements, pharmaceutical raw materials an …
  • Goldin Properties Holdings Ltd：企業の戦略・SWOT・財務分析
    Goldin Properties Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Goldin Properties Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Companhia Energetica de Sao Paulo：企業の発電所・SWOT分析2018
    Companhia Energetica de Sao Paulo - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Omega Pharma NV：企業の戦略的SWOT分析
    Omega Pharma NV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Corcept Therapeutics Inc (CORT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Corcept Therapeutics Inc (Corcept) is a research focused pharmaceutical company which discovers, develops and commercializes innovative therapeutics in the areas of psychiatric and metabolic diseases. The company focuses on developing drugs for the treatment of severe metabolic, oncologic an …
  • Pt Bank Central Asia Tbk：企業の戦略・SWOT・財務分析
    Pt Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Bank Central Asia Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Billabong International Limited (BBG)：企業の財務・戦略的SWOT分析
    Billabong International Limited (BBG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Virginia Electric and Power Co：企業の戦略的SWOT分析
    Virginia Electric and Power Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • PharmaCell BV-製薬・医療分野：企業M&A・提携分析
    Summary PharmaCell BV (PharmaCell) is a contract manufacturing organization that offers services for cellular therapies and regenerative medicine. The organization manufactures commercial cell therapy products in the European markets. Its services include cell culture scale-up, manufacturing of adva …
  • Arsenal Holdings PLC (AFC)：企業の財務・戦略的SWOT分析
    Arsenal Holdings PLC (AFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Toma Biosciences Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Toma Biosciences Inc (Toma Biosciences) is a provider of genome sequencing solutions. The company launched TOMA OS-Seq cancer assay to laboratories and researchers for the changes in tumors. Its products include reagent kits that are developed to detect genomic changes in cancer and TOMA OS- …
  • Amur Minerals Corporation：企業の戦略・SWOT・財務分析
    Amur Minerals Corporation - Strategy, SWOT and Corporate Finance Report Summary Amur Minerals Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Petrolia SE (PDR)：企業の財務・戦略的SWOT分析
    Summary Petrolia SE (Petrolia), formerly Petrolia E&P Holdings SE is an oil and gas company that offers well technology solutions. The company operates through two segments such as exploration and production (E&P), and oil service segments. Its E&P’s segment seeks to maximise field potential through …
  • GHD Pty Ltd：企業の戦略・SWOT・財務分析
    GHD Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary GHD Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆